Parexel acquired Vitrana, an AI-focused pharmacovigilance technology provider, to automate and streamline drug safety case processing for clinical trial programs. Parexel said the acquisition strengthens its ability to detect, extract, map, and reconcile safety signals while reducing manual workloads and bottlenecks. Vitrana’s platform is reported to automate high-volume tasks including case intake, narrative generation, and ongoing signal management. Parexel described performance benchmarks of a 60% reduction in case processing time and a 75% drop in manual reconciliation activities, framing the deal as part of broader AI investment in drug development operations.